We have located links that may give you full text access.
COMPARATIVE STUDY
ENGLISH ABSTRACT
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
[Contrast of losartan, fosinopril and amlodipine on cardiomyocyte apoptosis and left ventricular remolding in hypertensive rats].
Hunan Yi Ke da Xue Xue Bao = Hunan Yike Daxue Xuebao = Bulletin of Hunan Medical University 2001 October 29
OBJECTIVE: To investigate effects of losartan, fosinopril and amlodipine on cardiomyocyte apoptosis, cardiac remolding in the spontaneously hypertensive rats (SHR).
METHODS: SHRs were treated with lorsartan (SHR-L), fosinopril (SHR-F), amlodipine (SHR-A), and untreated (SHR-C) respectively for 8 and 16 weeks. Cardiomyocyte apoptotic index (APOI), left ventricular mass, left ventricular mass index (LVM, LVMI), and plasma and myocardium angiotensin II(PAng II, MAng II) concentrations were examined.
RESULTS: 1. The systolic blood pressure was decreased similarly in all treatment groups in 8 and 16 weeks. LVMIs were reduced significantly in all treatment groups. LVMI was significantly lower in SHR-F group than that in other two treatment groups in 16 weeks. 2. APOIs were decreased significantly in SHR-F group in 8 weeks and in all treatment groups, especially in SHR-F group in 16 weeks. 3. Compared with SHR-C group in both periods, PAng II and MAng II were significantly increased in SHR-L group, but MAng II concentration was only decreased significantly in SHR-F group in 8 weeks, and in SHR-F and SHR-A groups in 16 weeks.
CONCLUSION: Losartan, amlodipine, and especially fosinopril can inhibit cardiomyocyte apoptosis, prevent myocardial fibrosis, and reverse heart hypertrophy. Inhibition of myocardium rennin--angiotension--aldsteron system may be the mechanism of the three drugs' cardioprotective effects.
METHODS: SHRs were treated with lorsartan (SHR-L), fosinopril (SHR-F), amlodipine (SHR-A), and untreated (SHR-C) respectively for 8 and 16 weeks. Cardiomyocyte apoptotic index (APOI), left ventricular mass, left ventricular mass index (LVM, LVMI), and plasma and myocardium angiotensin II(PAng II, MAng II) concentrations were examined.
RESULTS: 1. The systolic blood pressure was decreased similarly in all treatment groups in 8 and 16 weeks. LVMIs were reduced significantly in all treatment groups. LVMI was significantly lower in SHR-F group than that in other two treatment groups in 16 weeks. 2. APOIs were decreased significantly in SHR-F group in 8 weeks and in all treatment groups, especially in SHR-F group in 16 weeks. 3. Compared with SHR-C group in both periods, PAng II and MAng II were significantly increased in SHR-L group, but MAng II concentration was only decreased significantly in SHR-F group in 8 weeks, and in SHR-F and SHR-A groups in 16 weeks.
CONCLUSION: Losartan, amlodipine, and especially fosinopril can inhibit cardiomyocyte apoptosis, prevent myocardial fibrosis, and reverse heart hypertrophy. Inhibition of myocardium rennin--angiotension--aldsteron system may be the mechanism of the three drugs' cardioprotective effects.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app